Opko Health (OPK) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Opko Health (OPK) PT Trimmed at Jefferies Post Q2, 'Buy' Maintained
August 13, 2014 7:54 AM EDTJefferies analyst Eun K. Yang, Ph.D trimmed his price target on Buy-rated Opko Health (NYSE: OPK) to $10.50 (from $11.00) following Q2 results but maintained a Buy rating.
Yang commented, "Narrower 2Q14 net loss of $25.5M (vs. ours of $31.8M) primarily on... More
OPKO Health (OPK) Reports Positive Top Line Results from Rayaldee Phase 3 Trial
August 11, 2014 4:31 PM EDTOPKO Health, Inc. (NYSE: OPK), announced successful top-line results from the first pivotal phase 3 trial of Rayaldee. This trial is one of two identical randomized, double-blind, placebo-controlled, multi-site studies intended to establish the safety and efficacy of Rayaldee as a new treatment for secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D... More
OPKO Health (OPK) Continues Higher Following Rayaldee IND Submission
August 8, 2014 3:48 PM EDTOPKO Health (NYSE: OPK) is looking to close higher for the fifth-straight session today, making a strong move back above the $9.25 in the process.
On Thursday afternoon, OPKO... More
OPKO Health (OPK) Submits IND for Rayaldee
August 7, 2014 3:49 PM EDTOPKO Health, Inc. (NYSE: OPK), announced the submission of an Investigational New Drug (IND) Application to the United States (U.S.) Food and Drug Administration (FDA) under which Rayaldee will begin clinical evaluation as an adjunctive therapy for the prevention of skeletal-related events (SREs) in patients with bone metastases... More
